Verastem Oncology and Dr. Lesley Roberts have launched the "Reimagine" campaign to move ovarian cancer treatments into earlier lines of therapy [1, 2].
The initiative aims to improve patient outcomes by accelerating regulatory approvals and ensuring women with the disease gain access to critical medications more quickly [1, 2].
Ovarian cancer treatment often follows a sequenced approach, where certain drugs are only administered after other therapies have failed. The "Reimagine" campaign advocates for a shift in this paradigm, pushing for the use of advanced therapies earlier in the treatment cycle to prevent disease progression [1, 2].
This push for earlier intervention follows a pattern of regulatory movement in the field. The FDA granted accelerated approval to the Avmapki Fakzynja co-packaged drug one year ago [2]. Verastem Oncology is leveraging this momentum to challenge existing clinical standards and advocate for a more aggressive approach to early-stage treatment [1, 2].
Dr. Roberts said the campaign focuses on the need to rethink how regulatory bodies and clinicians approach the timing of drug administration. By moving these therapies forward, the company intends to reduce the time patients spend waiting for secondary or tertiary options that may be more effective if used sooner [1, 2].
The campaign targets both policymakers and healthcare providers to highlight the gaps in current ovarian cancer care. Verastem Oncology seeks to establish a new standard of care that prioritizes efficacy over the traditional sequence of therapy lines [1, 2].
“The "Reimagine" campaign advocates for a shift in this paradigm”
The push to move ovarian cancer drugs into earlier lines of therapy represents a strategic attempt to change the standard of care from reactive to proactive. If successful, this shift could reduce the overall mortality rate by treating the disease with more potent combinations before the cancer develops resistance to primary therapies.
